[en] &lt;p&gt;OBJECTIVE: To analyze the access to medicines to treat non-communicable diseases&lt;br&gt;in Brazil according to socioeconomic, demographic, and health-related factors, from a&lt;br&gt;multidimensional perspective.&lt;/p&gt; &lt;p&gt;METHODS: Analysis of data from the National Survey on Access, Use and Promotion of&lt;br&gt;Rational Use of Medicines (PNAUM), household survey, sampling plan by conglomerates with&lt;br&gt;representativeness of the Brazilian population and large areas of the country, according to sex&lt;br&gt;and age domains. Data collected in 2013&ndash;2014 with sample of adults (&ge; 20 years) who reported&lt;br&gt;having non-communicable diseases and medical indication for use of medicines (n = 12,725).&lt;br&gt;We assessed the prevalence of access to medicines for self-reported non-communicable diseases,&lt;br&gt;considering four dimensions: availability, geographic accessibility, acceptability, and affordability.&lt;br&gt;We applied Pearson&rsquo;s Chi-square test to assess the statistical significance of the differences&lt;br&gt;between strata, considering the level of significance of 5%.&lt;/p&gt; &lt;p&gt;RESULTS: We found prevalence of 94.3%, 5.2%, and 0.5% for full, partial, and null access, respectively.&lt;br&gt;Higher prevalence was observed among seniors in the South compared to the Northeast; for those&lt;br&gt;who reported having one non-communicable disease compared to those who reported having two&lt;br&gt;or more; for those who needed one medicine compared to those who needed three or more; and for&lt;br&gt;those who self-assessed their health as good or very good. Geographic accessibility was similar in&lt;br&gt;the Unified Health System and in the private pharmacies (72.0%). Total availability of medicines was&lt;br&gt;45.2% in the Unified Health System, 67.4% in the Popular Pharmacy Program, and 88.5% in private&lt;br&gt;pharmacies. Acceptability was 92.5% in the Unified Health System, 97.8% in the Popular Pharmacy&lt;br&gt;Program, and 98.7% in private pharmacies. As to affordability, 2.6% of the individuals failed to take&lt;br&gt;the medicines they should in the 30-day period prior to the interview due to financial difficulty.&lt;/p&gt; &lt;p&gt;CONCLUSIONS: Prevalence of full access to medicines for non-communicable diseases in&lt;br&gt;Brazil is high and presents significant differences for age group, region of the country, number&lt;br&gt;of non-communicable diseases, and for medicines prescribed and self-assessment of health. The&lt;br&gt;major barriers to access to medicines were identified in the dimensions analyzed.&lt;/p&gt;

[pt] &lt;p&gt;OBJETIVO:&nbsp;Analisar o acesso a medicamentos para tratar doen&ccedil;as cr&ocirc;nicas n&atilde;o transmiss&iacute;veis no Brasil segundo fatores socioecon&ocirc;micos, demogr&aacute;ficos e de sa&uacute;de, sob perspectiva multidimensional.&lt;/p&gt; &lt;p&gt;M&Eacute;TODOS:&nbsp;An&aacute;lise de dados da Pesquisa Nacional sobre Acesso, Utiliza&ccedil;&atilde;o e Promo&ccedil;&atilde;o do Uso Racional de Medicamentos (PNAUM), inqu&eacute;rito domiciliar, plano amostral por conglomerados com representatividade da popula&ccedil;&atilde;o brasileira e grandes regi&otilde;es do Pa&iacute;s, segundo dom&iacute;nios de sexo e idade. Dados coletados em 2013-2014 com amostra constitu&iacute;da por adultos (&ge; 20 anos) que referiram ter doen&ccedil;as cr&ocirc;nicas n&atilde;o transmiss&iacute;veis e indica&ccedil;&atilde;o m&eacute;dica para usar medicamentos (n = 12.725). Avaliou-se a preval&ecirc;ncia de acesso aos medicamentos para doen&ccedil;as cr&ocirc;nicas n&atilde;o transmiss&iacute;veis autorreferidas, considerando quatro dimens&otilde;es: disponibilidade, acessibilidade geogr&aacute;fica, aceitabilidade e capacidade aquisitiva. Aplicou-se teste Qui-quadrado de Pearson para avaliar a signific&acirc;ncia estat&iacute;stica das diferen&ccedil;as entre os estratos, considerando o n&iacute;vel de signific&acirc;ncia de 5%.&lt;/p&gt; &lt;p&gt;RESULTADOS:&nbsp;Foram encontradas preval&ecirc;ncias de 94,3%, 5,2% e 0,5% para acesso total, parcial e nulo, respectivamente. Maiores preval&ecirc;ncias ocorreram entre os idosos, na regi&atilde;o Sul comparada &agrave; regi&atilde;o Nordeste; naqueles que referiram ter uma doen&ccedil;a cr&ocirc;nica n&atilde;o transmiss&iacute;vel comparados aos que referiram ter duas ou mais; naqueles que precisavam de um medicamento comparados aos que precisavam de tr&ecirc;s ou mais; e naqueles que autoavaliaram sua sa&uacute;de como boa ou muito boa. A acessibilidade geogr&aacute;fica foi semelhante no Sistema &Uacute;nico de Sa&uacute;de e nas farm&aacute;cias privadas (72,0%). A disponibilidade total de medicamentos foi de 45,2% no Sistema &Uacute;nico de Sa&uacute;de, 67,4% no Programa Farm&aacute;cia Popular e 88,5% nas farm&aacute;cias privadas. A aceitabilidade foi de 92,5% no Sistema &Uacute;nico de Sa&uacute;de, 97,8% no Programa Farm&aacute;cia Popular e 98,7% nas farm&aacute;cias privadas. Quanto &agrave; capacidade aquisitiva, 2,6% dos indiv&iacute;duos n&atilde;o tomou os medicamentos que deveria nos 30 dias anteriores &agrave; entrevista devido &agrave; dificuldade financeira.&lt;/p&gt; &lt;p&gt;CONCLUS&Otilde;ES:&nbsp;A preval&ecirc;ncia do acesso total aos medicamentos para doen&ccedil;as cr&ocirc;nicas n&atilde;o transmiss&iacute;veis no Brasil &eacute; alta e apresenta diferen&ccedil;as significativas por faixa et&aacute;ria, regi&atilde;o do Pa&iacute;s, n&uacute;mero de doen&ccedil;as cr&ocirc;nicas n&atilde;o transmiss&iacute;veis e de medicamentos prescritos e autoavalia&ccedil;&atilde;o da sa&uacute;de. Foram identificadas as principais barreiras ao acesso a medicamentos nas dimens&otilde;es analisadas.&lt;/p&gt;